Form 8-K - Current report:
SEC Accession No. 0000950170-25-042317
Filing Date
2025-03-20
Accepted
2025-03-20 07:02:00
Documents
13
Period of Report
2025-03-20
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K spry-20250320.htm   iXBRL 8-K 61225
2 EX-99.1 spry-ex99_1.htm EX-99.1 272284
3 GRAPHIC img41264513_0.jpg GRAPHIC 32408
  Complete submission text file 0000950170-25-042317.txt   524172

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT spry-20250320.xsd EX-101.SCH 32095
15 EXTRACTED XBRL INSTANCE DOCUMENT spry-20250320_htm.xml XML 4893
Mailing Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130
Business Address 11682 EL CAMINO REAL, SUITE 120 SAN DIEGO CA 92130 858-771-9307
ARS Pharmaceuticals, Inc. (Filer) CIK: 0001671858 (see all company filings)

EIN.: 811489190 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39756 | Film No.: 25754461
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)